MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.m. ET Location: Virtual Webcast: Available via conference website TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Time: 1:10 p.m. ET Location: Boston Marriott Copley Place, Boston, MA Webcast: Available via conference website A live webcast and replay of each presentation will be accessible through the Events & Presentations section of the Investor Relations area of MediWound's website. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company's FDA-approved biologic, NexoBrid(R), is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound's late-stage pipeline product, EscharEx(R), is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management. For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter). MediWound Contacts: Hani Luxenburg Daniel Ferry
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
